Safety and Effectiveness of Remote Ischemic Conditioning Combined With Intravenous Thrombolysis in Treating Acute Ischemic Stroke
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Frequency of adverse events during follow-up
研究概览
简要总结
The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning combined with intravenous thrombolysis in treating acute ischemic stroke.
详细描述
In this study, cases of ischemic stroke who undergo intravenous thrombolysis within 4.5 hours from onset are included. The experimental group receive basic treatment and remote ischemic conditioning for 200mmHg, 2 times within 6 hours to 24 hours from thrombolysis. The control group receive basic treatment and remote ischemic conditioning control for 60mmHg, 2 times within 6 hours to 24 hours from thrombolysis . Two groups will be followed up for 90 days to evaluate the efficacy and safety of remote ischemic conditioning combined with intravenous thrombolysis in treating acute ischemic stroke.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age≥18 years, < 80 years, regardless of sex;
- •Patients with clinically definite diagnosis of acute ischemic stroke and undergo intravenous thrombolysis;
- •Baseline NIHSS >= 5, and <= 25;
- •Baseline GCS ≥8;
- •Signed and dated informed consent is obtained
排除标准
- •Patients who undergo endovascular treatment;
- •mRS ≥ 2 before the onset of the disease;
- •Double upper limbs or lower limbs paralysis was found in this case;
- •Active bleeding of organs within 6 months of admission or current, including cerebral hemorrhage, subarachnoid hemorrhage, gastrointestinal hemorrhage, fundus hemorrhage and so on;
- •Other intracranial lesions, such as cerebrovascular malformation cerebral venous diseases, tumor and other diseases involving the brain;
- •Concurrent use of anticoagulation drugs including Warfarin, dabigatran, rivaroxaban;
- •Severe organ dysfunction or failure;
- •Patients suffering from severe hematological diseases or severe coagulation disorder dysfunction
- •Those who have a history of severe trauma or had major surgery within 6 months prior to admission;
- •Those who have a history of atrial fibrillation;
- •The patients who have the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture or vascular injury in the upper limb#Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc;
- •Pregnant or lactating women;
- •Previous remote ischemic conditioning therapy or similar treatment;
- •Patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons;
- •Severe hepatic and renal dysfunction;
- •Unwilling to be followed up or treated for poor compliance;
- •He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission;
- •Other conditions that the researchers think are not suitable for the group.
结局指标
主要结局
Frequency of adverse events during follow-up
时间窗: 3 months
Severe adverse events through day-90 after the onset of acute ischemic stroke.
Frequency of adverse events during hospitalization
时间窗: 7 days
All adverse events until day-7 or discharge (whichever is earlier)
次要结局
- National Institute of Health stroke scale (NIHSS) at 7 days from onset or discharge(7 days)
- Proportion of patients with Modified Rankin Scale (mRS) Score 0-2(3 months)
研究者
Yi Yang
Associated Dean of First Hospital of Jilin University
The First Hospital of Jilin University